0000000000481951

AUTHOR

Massimiliano Copetti

0000-0002-7960-5947

showing 5 related works from this author

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to pre…

2014

Background Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. Methods mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients a…

MaleOncologyCHOPEquilibrative nucleoside transporter 1BioinformaticsDeoxycytidineCohort StudiesPancreatic ductal adenocarcinomachemistry.chemical_compoundMedicine(all)Transcription Factor CHOPbiologyDCKGeneral MedicineMiddle AgedSurvival RateDisease ProgressionAdenocarcinomaFemaleMRP1DeoxycytidineMultidrug Resistance-Associated ProteinsCarcinoma Pancreatic Ductalmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaMalignancyhENT1General Biochemistry Genetics and Molecular BiologyEquilibrative Nucleoside Transporter 1Internal medicinemedicineHumansRNA MessengerSurvival rateAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchRECPAMmedicine.diseaseGemcitabineGemcitabinechemistrybiology.proteinPancreatic ductal adenocarcinoma hENT1 CHOP MRP1 DCK RECPAMbusinessTranscription Factor CHOPCHOP
researchProduct

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

2010

<i>Objectives:</i> FOLFOX-4 and FOLFIRI are considered equivalent in terms of activity and efficacy as first-line chemotherapy in metastatic colorectal cancer (mCRC). The monoclonal antibody (mAb) cetuximab showed intrinsic activity as a single agent in mCRC and was approved in combination with CPT-11 for patients who failed previous CPT-11-based treatment. The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients. <i>Methods:</i> Untreated patients with measurable metastatic disease and expressing epidermal growth factor receptor (EGFR) received cetuximab at a loading dose of 400 mg/m<sup>2…

OncologyMaleCancer ResearchLung NeoplasmsOrganoplatinum CompoundsSettore MED/06 - Oncologia MedicaColorectal cancerMetastaseLeucovorinPhases of clinical researchCetuximabColorectal Neoplasmmedicine.disease_causeMetastasisFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinFOLFOX-4CetuximabLiver NeoplasmsAntibodies MonoclonalGeneral MedicineMiddle AgedErbB ReceptorsColorectal carcinomaOncologyLiver NeoplasmFOLFIRIFemaleKRASFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAntibodies Monoclonal HumanizedBRAFProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsKRASmedicineHumansAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundCancerras Proteinmedicine.diseasedigestive system diseasesSurgeryLung NeoplasmMutationras ProteinsReceptor Epidermal Growth FactorbusinessBRAF; Cetuximab; Colorectal carcinoma; FOLFOX-4; KRAS; Metastases; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; ras Proteins; Oncology; Cancer ResearchOncology
researchProduct

Tract-specific white matter structural disruption in patients with bipolar disorder

2011

Benedetti F, Absinta M, Rocca MA, Radaelli D, Poletti S, Bernasconi A, Dallaspezia S, Pagani E, Falini A, Copetti M, Colombo C, Comi G, Smeraldi E, Filippi M. Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord 2011: 13: 414–424. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S. Objectives:  A growing body of evidence suggests that, independent of localized brain lesions, mood disorders can be associated with dysfunction of brain networks involved in the modulation of emotional and cognitive behavior. We used diffusion tensor (DT) tractography to quantify the presence and extent of structural injury to the connections betwe…

Cingulate cortexmedicine.diseaseBrain mapping030227 psychiatry3. Good healthWhite matter03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinemedicine.anatomical_structurePosterior cingulateFractional anisotropymedicineMajor depressive disorderBipolar disorderPsychologyNeuroscience030217 neurology & neurosurgeryBiological PsychiatryTractographyBipolar Disorders
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acq…

2018

BACKGROUND: To evaluate the prognostic accuracy of proadrenomedullin (proADM) in comparison with and in addition to the Multidimensional Prognostic Index (MPI), a validated predictive tool for mortality derived from a comprehensive geriatric assessment (CGA) to predict one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP). METHODS: All patients aged 65 years and older, consecutively admitted to an acute geriatric ward with a diagnosis of CAP from February to July 2012. At admission and at discharge they were submitted to a standard CGA in order to calculate MPI. Moreover, plasma samples were taken at baseline and after one, three and five days of ho…

0301 basic medicineMalemedicine.medical_specialtySeverity of Illness Index03 medical and health sciencesAdrenomedullin0302 clinical medicinePatient AdmissionOlder patientsCommunity-acquired pneumoniaPredictive Value of TestsRisk FactorsInternal medicineSeverity of illnessRisk of mortalityMedicineHumansProspective StudiesProtein PrecursorsProspective cohort studyGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelGeneral MedicinePneumoniamedicine.diseasePrognosisPatient DischargeCommunity-Acquired InfectionsPneumonia030104 developmental biology030220 oncology & carcinogenesisPredictive value of testsFemalebusinessPanminerva medica
researchProduct